Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been given an average rating of “Moderate Buy” by the twelve research firms that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $25.50.

A number of equities analysts have recently issued reports on KURA shares. Scotiabank lowered their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. BTIG Research downgraded Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. Jefferies Financial Group lowered their price objective on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Finally, Bank of America lowered their price objective on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd.

Insider Buying and Selling

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 over the last 90 days. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. bought a new position in shares of Kura Oncology in the fourth quarter valued at approximately $38,769,000. Millennium Management LLC lifted its holdings in shares of Kura Oncology by 180.1% in the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock valued at $20,618,000 after purchasing an additional 1,521,954 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Kura Oncology in the fourth quarter valued at approximately $8,518,000. Marshall Wace LLP bought a new position in shares of Kura Oncology in the fourth quarter valued at approximately $8,265,000. Finally, D. E. Shaw & Co. Inc. lifted its holdings in shares of Kura Oncology by 172.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,151,195 shares of the company’s stock valued at $10,027,000 after purchasing an additional 727,987 shares in the last quarter.

Kura Oncology Price Performance

Kura Oncology stock opened at $7.27 on Friday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $587.09 million, a PE ratio of -3.08 and a beta of 0.85. Kura Oncology has a 12 month low of $6.79 and a 12 month high of $23.48. The stock has a 50-day moving average price of $7.81 and a two-hundred day moving average price of $12.61.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. Analysts expect that Kura Oncology will post -2.44 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.